Christopher P Cannon MDProfessor of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women’s Hospital.
Dr. Cannon has published over 1000 original articles, reviews, book chapters or electronic publications in the field of acute coronary syndromes and prevention. He has received numerous awards, including the Alfred Steiner Research Award, and the Upjohn Achievement in Research Award, and leadership awards from the American College of Cardiology and the American Heart Association.
He has long served as a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18 and PROVE IT-TIMI 22. Dr. Cannon is the principal investigator for three ongoing trials, IMPROVE IT, SOLID-TIMI 52, and REVEAL-HPS3/TIMI 55 studying three lipid-modifying strategies for secondary prevention. Dr. Cannon also collaborates with other investigators, including the Harvard Clinical Research Institute (HCRI) to lead other clinical trials and registry projects.
He is editor-in-chief of the Science and Quality section of ACC’s website, Cardiosource (www.cardiosource.org) as well as the journal Critical Pathways in Cardiology and a 70-book series Contemporary Cardiology, and Deputy Editor-in-Chief of Clinical Cardiology. He has authored or edited 15 books, including Evidence Based Cardiology and The New Heart Disease Handbook for patients.
Recent Contributions to PracticeUpdate:
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- Effect of Empagliflozin on the Clinical Stability in HFrEF
- MY APPROACH to Patients Taking Aspirin for Primary Prevention
- PCSK9 Inhibitor Price Reduction Essential for Cost-Effectiveness
- Evacetrapib Does Not Reduce Cardiovascular Risk in High-Risk Vascular Disease
- Antiplatelet Therapy for Patients With Stable CAD and AF on Oral Anticoagulants
- Coxibs and Diclofenac High-Risk NSAIDs for Vascular Events While Ibuprofen on Shaky Ground and Naproxen Appears Safe